CompletedNot Applicable

Impact of Ketoflex 12/3 Diet on Parkinson's Disease Symptoms: A Clinical Study

Turkey (Türkiye)40 participantsStarted 2024-03-30

Plain-language summary

This study aims to investigate the effects of the Ketoflex 12/3 diet on motor and non-motor symptoms in patients with Parkinson's disease. Participants will follow the Ketoflex 12/3 dietary regimen, and their cognitive function, motor symptoms, sleep patterns, gastrointestinal health, and overall well-being will be assessed through standardized clinical scales. The study will help determine whether a plant-based ketogenic diet combined with intermittent fasting can have a beneficial impact on Parkinson's disease progression.

Who can participate

Age range40 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with Parkinson's disease * Age between 40-85 years * Native Turkish speakers * Able to comply with the study protocol Exclusion Criteria: * History of alcohol or substance dependence * Diagnosis of chronic renal failure * Presence of neuromuscular disorders * Having amalgam dental fillings and/or failure to remove them according to the SMART protocol * Severe vitamin deficiencies that have not been corrected prior to the study

What they're measuring

Change in Motor Symptoms as Measured by the Unified Parkinson's Disease Rating Scale (UPDRS)

Timeframe: Baseline and 6 months

Trial details

NCT IDNCT06892418

SponsorIstanbul Medipol University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-30

View on ClinicalTrials.gov More Parkinson's Disease trials